YL-17231

N/A

Report date: 2023/12/05 10:59:09
NME

Base Information

Drug NameYL-17231
Drug Alias NameYL-17231YL17231TEB-17231
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYL-Pharma
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYL-Pharma
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A